Asarfi Hospital Limited has notified BSE Limited of its 1st Board Meeting for the financial year 2026-27, scheduled for Monday, May 11, 2026. The intimation, dated May 4, 2026, was filed under Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the financial year ended March 31, 2026.

Board Meeting Details

The following key details have been disclosed in the regulatory filing:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, Asarfi Hospital Limited has also announced a trading window closure for its designated persons. The trading window for dealing in the securities of the company remains closed from April 1, 2026 to May 31, 2026 (both days inclusive). The company has confirmed that all designated persons have been duly informed of this restriction.

The filing was submitted by CS Sudipa Singh, Company Secretary and Compliance Officer of Asarfi Hospital Limited, on behalf of the company. The company is headquartered in Dhanbad, Jharkhand, and operates under CIN: L85110JH2005PLC011673.

Asarfi Hospital Limited has delivered robust financial performance for the quarter ended 31st December 2025, showcasing significant growth across key operational and profitability metrics. The Dhanbad-based healthcare provider announced its Q3FY26 results following a Board meeting held on 9th February 2026, with the company filing its regulatory disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

The company's standalone financial results reveal impressive year-on-year growth, with revenue from operations reaching ₹4,605.87 lakhs in Q3FY26 compared to ₹3,289.01 lakhs in the corresponding quarter of the previous year. Net profit after tax showed even stronger performance, climbing to ₹548.29 lakhs from ₹271.93 lakhs in Q3FY25.

Operational Excellence and Margin Expansion

The company demonstrated strong operational momentum with EBITDA margin reaching 22% and PAT margin at 12% for Q3FY26. The growth was driven by higher patient volumes, improved Average Revenue Per Occupied Bed (ARPOB), and enhanced case mix across both healthcare units. IPD revenue grew 42% year-on-year while OPD revenue increased 37%, supported by rising patient volumes and higher realizations.

Nine-Month Performance

The nine-month period ended 31st December 2025 demonstrated sustained growth trajectory, with revenue from operations increasing 46.04% to ₹12,656.94 lakhs compared to ₹8,667.37 lakhs in the corresponding period of FY25. Net profit after tax for the nine-month period reached ₹1,298.34 lakhs, representing an 81.57% increase from ₹715.10 lakhs in the previous year.

Specialty-Led Growth Strategy

The company's growth was driven by high-acuity segments including Cardiology and Neurosciences in the Super-Specialty unit, and Head & Neck and Haemato Oncology in the Cancer unit. This specialty-led approach has improved the overall revenue mix and complexity of care, contributing to enhanced profitability metrics. The company operates as a leading healthcare provider with a 20-year track record, running two hospitals across super-specialty and oncology care.

Balance Sheet Strength and Regulatory Compliance

The company's balance sheet as at 31st December 2025 reflects strengthened financial position with total assets increasing to ₹18,555.12 lakhs from ₹16,430.57 lakhs as at 31st March 2025. Cash and cash equivalents showed substantial improvement, rising to ₹1,701.79 lakhs from ₹131.56 lakhs, enhancing liquidity position. The financial results were audited by M/s R. K. Thakkar & Co., Chartered Accountants, who issued unmodified audit opinions on both standalone and consolidated financial statements.